<?xml version="1.0"?>

<document>
	<title>Lipids in cystic fibrosis.</title>

	<author>Rosenlund-M-L.</author>
	<author>Walsh-E-P.</author>
	<author>Scott-D-A.</author>
	<author>Kritchevsky-D.</author>

	<source>Curr-Concepts-Nutr. 1979. 8. P 219-27. (REVIEW).</source>

	<abstract>There are certain aspects of the symptomatology of cystic fibrosis
   that bear a resemblance to those of essential fatty acid deficiency.
   We fed a group of patients essential fatty acids orally since
   intravenous administration is not a practical method for long term
   treatment.  Results of the study were varied.  Although some response
   was noted in all patients, there were no consistent clinical changes
   seen in every patient.  The oral EFA therapy effected no change in
   sputum cultures.  After one year of EFA, the sweat sodium
   concentration was lower in all but one patient.  The clinical aspect
   of our study is small, but promising.  The results suggest a role for
   EFAs in the care of CF.  Whether EFA is a factor in the etiology of
   CF or merely a manifestation of malabsorption requires further
   investigation.</abstract>

	<majorsubject>CYSTIC-FIBROSIS: dh</majorsubject>
	<majorsubject>DIETARY-FATS</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>CELLS-CULTURED</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CHILD-PRESCHOOL</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: bl, me</minorsubject>
	<minorsubject>FATTY-ACIDS: bl, me</minorsubject>
	<minorsubject>FATTY-ACIDS-ESSENTIAL: df</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>FIBROBLASTS: me</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>OILS</minorsubject>
	<minorsubject>REVIEW</minorsubject>
	<minorsubject>SUPPORT-U-S-GOVT-P-H-S</minorsubject>

	<reference>001   WARWICK WJ            JAMA                           238  2159 977</reference>
	<reference>002   BURR GO               J BIOL CHEM                     86   587 930</reference>
	<reference>003   KRAMAR J              J NUTR                          50   149 953</reference>
	<reference>004   HANSEN AE             TEX REP BIOL MED                 9   491 951</reference>
	<reference>005   HANSEN AE             PEDIATRICS                      31   171 963</reference>
	<reference>006   ELLIOTT RB            PEDIATR RES                      7   427 973</reference>
	<reference>007   ELLIOTT RB            PEDIATRICS                      57   474 976</reference>
	<reference>008   SHWACHMAN H           AM J DIS CHILD                  96     6 958</reference>
	<reference>009   GIBSON LE             PEDIATRICS                      23   545 959</reference>
	<reference>010   KUO PT                J CLIN INVEST                   44  1924 965</reference>
	<reference>011   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966</reference>
	<reference>012   WIESE HF              AM J CLIN NUTR                  18   155 966</reference>
	<reference>013   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972</reference>
	<reference>014   BENNETT MJ            AM J CLIN NUTR                  20   415 967</reference>
	<reference>015   ROSENLUND ML          NATURE                         251   719 974</reference>
	<reference>016   ROSENLUND ML          PEDIATRICS                      59   428 977</reference>
	<reference>017   MOHRHAUER H           J LIPID RES                      4   151 963</reference>
	<reference>018   PELUFFO RO            BIOCHIM BIOPHYS ACTA           441    25 976</reference>
	<reference>019   SPRECHER H            IN: KUNAU WH                           1 977</reference>
	<reference>020   HOWARD BV             BIOCHIM BIOPHYS ACTA           187   293 969</reference>

	<citation>1   PARNHAM MJ            AGENTS ACTIONS                  14   223 984</citation>

</document>
